Concepedia
3
Publications
425
Citations
H-Index
2017
Active since
Affiliations
AstraZeneca (Sweden)(Current)
University of Gothenburg
Mats Kvarnström is an author at AstraZeneca (Sweden).
Publications per year
2017–2018
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson et al. · Diabetologia · 2018 · 368 citations · Full text
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial
Erik S.G. Stroes, Andrey V. Susekov, Tjerk W.A. de Bruin et al. · Journal of clinical lipidology · 2017 · 38 citations · Full text
Importance of pancreatic exocrine dysfunction in patients with type 2 diabetes: A randomized crossover study
Björn Lindkvist, Catarina Nilsson, Mats Kvarnström et al. · Pancreatology · 2018 · 19 citations · Full text
Rows per page
1–3 of 3